Pacira Pharmaceuticals Inc (PCRX) : Dw Partners Lp has sold out all of its stake in Pacira Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 64,500 shares of Pacira Pharmaceuticals Inc which is valued at $2.8 Million.
Other Hedge Funds, Including , Blackrock Fund Advisors boosted its stake in PCRX in the latest quarter, The investment management firm added 18,120 additional shares and now holds a total of 1,582,234 shares of Pacira Pharmaceuticals Inc which is valued at $68.4 Million. Pacira Pharmaceuticals Inc makes up approx 0.02% of Blackrock Fund Advisors’s portfolio. Airain Ltd sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 3,655 shares of PCRX which is valued $157,933. Parametrica Management Ltd sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 4,231 shares of PCRX which is valued $200,380.
Pacira Pharmaceuticals Inc closed down -2.58 points or -5.61% at $43.44 with 21,90,533 shares getting traded on Wednesday. Post opening the session at $45.62, the shares hit an intraday low of $42.1401 and an intraday high of $45.62 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 2, 2016. Analyst had a consensus of $0.09. The company had revenue of $65.50 million for the quarter, compared to analysts expectations of $66.82 million. The company’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Shares were Reiterated by Wedbush on May 25, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $113 .Shares were Reiterated by Mizuho on May 3, 2016 to “Buy” and Lowered the Price Target to $ 64 from a previous price target of $71 .Mizuho Initiated Pacira Pharmaceuticals Inc on Apr 19, 2016 to “Buy”, Price Target of the shares are set at $79.
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.